Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Open Access
- 16 May 2008
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 6 (1) , 25
- https://doi.org/10.1186/1479-5876-6-25
Abstract
Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering FcγRIII on natural killer (NK) cells. This study addresses the correlation between overall NK function and trastuzumab's clinical activity.Keywords
This publication has 35 references indexed in Scilit:
- Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2Cancer Research, 2007
- The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By CytokinesClinical Cancer Research, 2007
- Natural Killer Cells Produce T Cell–Recruiting Chemokines in Response to Antibody-Coated Tumor CellsCancer Research, 2006
- Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast CancersJournal of Clinical Oncology, 2005
- Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding FormatJournal of Biological Chemistry, 2004
- A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing MalignanciesClinical Cancer Research, 2004
- The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth InhibitionJournal of Biological Chemistry, 2003
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cellsEuropean Journal of Immunology, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987